We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+23.56%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$135M
AUM Growth
+$62.2M
Cap. Flow
+$48.4M
Cap. Flow %
35.91%
Top 10 Hldgs %
44.79%
Holding
162
New
9
Increased
113
Reduced
25
Closed
15

Top Buys

Rank Stock Value
1
ETP
Energy Transfer Partners L.p.
ETP
+$4.79M
2
EEP
Enbridge Energy Partners
EEP
+$3.1M
3
PAA icon
Plains All American Pipeline
PAA
+$2.86M
4
WPZ
Williams Partners L.P.
WPZ
+$2.84M
5
ETP
Energy Transfer Partners, L.P.
ETP
+$2.77M

Top Sells

Rank Stock Value
1
TRGP icon
Targa Resources
TRGP
+$572K
2
XNPT
XENOPORT, INC.
XNPT
+$458K
3
MDVN
MEDIVATION, INC.
MDVN
+$291K
4
TBPH icon
Theravance Biopharma
TBPH
+$289K
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$275K

Sector Composition

Rank Sector Weight
1 Energy 64.17%
2 Healthcare 25.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
101
DELISTED
Ignyta, Inc.
RXDX
$242K 0.18%
44,599
+23,282
+109% +$155K
BCRX icon
102
BioCryst Pharmaceuticals
BCRX
$2.38B
$241K 0.18%
84,907
+58,661
+224% +$182K
FPRX
103
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$241K 0.18%
5,837
-484
-8% -$21.1K
ISEE
104
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$240K 0.18%
4,702
+1,192
+34% +$59.2K
SGMO
105
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$239K 0.18%
41,249
+12,188
+42% +$77.7K
KDNY
106
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$238K 0.18%
4,202
+2,609
+164% +$159K
LOXO
107
DELISTED
Loxo Oncology, Inc
LOXO
$237K 0.18%
10,231
+1,519
+17% +$37.8K
IBRX icon
108
ImmunityBio
IBRX
$7.75B
$236K 0.18%
37,895
+23,332
+160% +$181K
MCRB icon
109
Seres Therapeutics
MCRB
$50.6M
$235K 0.17%
405
+76
+23% +$44.6K
CNCE
110
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$235K 0.17%
20,939
+8,275
+65% +$105K
XLRN
111
DELISTED
Acceleron Pharma
XLRN
$235K 0.17%
6,910
+1,154
+20% +$37.5K
JUNO
112
DELISTED
Juno Therapeutics, Inc.
JUNO
$231K 0.17%
6,017
+664
+12% +$27.6K
ARWR icon
113
Arrowhead Research
ARWR
$12.2B
$230K 0.17%
43,272
-1,442
-3% -$8.23K
PTLA
114
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$230K 0.17%
9,735
+4,503
+86% +$111K
AGTC
115
DELISTED
Applied Genetic Technologies Corporation
AGTC
$229K 0.17%
+16,223
New +$253K
LJPC
116
DELISTED
La Jolla Pharmaceutical Company
LJPC
$229K 0.17%
14,291
+4,646
+48% +$83.3K
PBYI icon
117
Puma Biotechnology
PBYI
$408M
$228K 0.17%
7,666
+4,345
+131% +$136K
ALNY icon
118
Alnylam Pharmaceuticals
ALNY
$35.9B
$226K 0.17%
4,078
+1,279
+46% +$80.6K
SRNE
119
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$226K 0.17%
40,438
+4,308
+12% +$27.5K
EPZM
120
DELISTED
Epizyme, Inc
EPZM
$223K 0.17%
21,750
+5,350
+33% +$59.7K
AVXS
121
DELISTED
AveXis, Inc. Common Stock
AVXS
$223K 0.17%
+5,869
New +$198K
FOLD
122
DELISTED
Amicus Therapeutics
FOLD
$222K 0.16%
40,705
+13,285
+48% +$92.9K
INO icon
123
Inovio Pharmaceuticals
INO
$83.9M
$222K 0.16%
2,005
-1,369
-41% -$166K
AKBA icon
124
Akebia Therapeutics
AKBA
$327M
$221K 0.16%
29,590
+8,160
+38% +$71.2K
TCRT icon
125
Alaunos Therapeutics
TCRT
$4.69M
$221K 0.16%
268
+75
+39% +$81.7K
3 4
5
6 7

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
OC
Optima Capital Beaverton, Oregon $215M AUM 17.28% 1-Year Est. Return
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return

Virtus ETF Advisers's Q2 2016 Portfolio in Review

As of Q2 2016, Virtus ETF Advisers held 162 positions worth $135M, up 86% from $72.6M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Virtus ETF Advisers deployed $48.4M of net new capital in Q2 2016, opening 9 new positions and adding to 113 existing holdings. Its largest new stake was Cheniere Energy: 11,685 shares worth $350K.

By sector, the portfolio is most concentrated in Energy at 64% of assets, up from 49% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was Targa Resources, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q2 2016 buy was Cheniere Energy: 11,685 shares worth $350K.
  • Virtus ETF Advisers added most to Energy Transfer Partners L.p. in Q2 2016, an estimated $4.79M increase.
  • Virtus ETF Advisers's biggest Q2 2016 reduction was Targa Resources, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited XENOPORT, INC. in Q2 2016, selling an estimated $458K.
  • Virtus ETF Advisers's ten largest holdings make up 45% of its $135M portfolio in Q2 2016.
  • Virtus ETF Advisers opened 9 new positions and closed 15 in Q2 2016.
  • Virtus ETF Advisers's portfolio value rose 86% quarter-over-quarter to $135M.

Based on Virtus ETF Advisers's 13F filing for Q2 2016, filed 15 Aug 2016.